“The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis”. Farmeconomia. Health Economics and Therapeutic Pathways 20, no. 1 (July 10, 2019). Accessed December 28, 2025. https://journals.seedstm.com/index.php/FE/article/view/1435.